The clinical-stage biopharmaceutical company is headquartered in Fremont, California, and focuses on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its proprietary transdermal microneedle system. Its primary product candidate is Qtrypta (M207), which is the proprietary formulation of zolmitriptan delivered utilizing the system. Zosano Pharma aims to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action. The company's system offers rapid and consistent drug delivery, improved ease of use and room-temperature stability, all of which are benefits that the company believes are often unavailable using oral formulations or injections and offer important therapeutic and practical advantages that address unmet needs with large patient populations.